Management of pulmonary arterial hypertension

Journal of the American College of Cardiology

Volumn 65, Issue 18, 2015, Pages 1976-1997

  McLaughlin, Vallerie V ^a   Shah, Sanjiv J ^b   Souza, Rogerio ^c   Humbert, Marc ^d,e,f  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e BICÊTRE HOSPITAL   (France)

^f CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

echocardiography; endothelin receptor antagonists; hemodynamics; phosphodiesterase type 5 inhibitors; prostacyclins; pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; AMINOREX; ANTICOAGULANT AGENT; BENFLUOREX; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DASATINIB; DEXFENFLURAMINE; ENDOTHELIN; FENFLURAMINE; GUANYLATE CYCLASE ACTIVATOR; MACITENTAN; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; RIOCIGUAT; TREPROSTINIL; ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR ANTAGONIST;

ARTICLE; BALLOON ATRIAL SEPTOSTOMY; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG SAFETY; ECHOCARDIOGRAPHY; EXTRACORPOREAL CIRCULATION; HEART CATHETERIZATION; HEART LUNG TRANSPLANTATION; HEART RIGHT VENTRICLE; HERITABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOXIA; IDIOPATHIC DISEASE; INTENSIVE CARE; PATHOGENESIS; PATIENT CARE; PATIENT COUNSELING; PATIENT EDUCATION; PERIOPERATIVE PERIOD; PORTAL HYPERTENSION; PRIORITY JOURNAL; PULMONARY CAPILLARY HEMANGIOMATOSIS; PULMONARY HYPERTENSION; PULMONARY VASCULAR HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; SCHISTOSOMIASIS; SURGICAL APPROACH; ANAMNESIS; CLASSIFICATION; EXERCISE TEST; EXTRACORPOREAL OXYGENATION; HEART ATRIUM SEPTUM; HEART VENTRICLE; HYPERTENSION, PULMONARY; INTIMA; LUNG TRANSPLANTATION; PATHOLOGY; PHYSICAL EXAMINATION; PULMONARY ARTERY; REGISTER; SURGERY; TUNICA MEDIA; VASCULAR REMODELING;

ANTIHYPERTENSIVE AGENTS; ATRIAL SEPTUM; CALCIUM CHANNEL BLOCKERS; CARDIAC CATHETERIZATION; ECHOCARDIOGRAPHY; ENDOTHELIN RECEPTOR ANTAGONISTS; EXERCISE TEST; EXTRACORPOREAL MEMBRANE OXYGENATION; HEART VENTRICLES; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; MEDICAL HISTORY TAKING; PHOSPHODIESTERASE 5 INHIBITORS; PHYSICAL EXAMINATION; PULMONARY ARTERY; REGISTRIES; TUNICA INTIMA; TUNICA MEDIA; VASCULAR REMODELING;

EID: 84928945831     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.03.540     Document Type: Review

References (111)

1. N. Galie, M.M. Hoeper, and M. Humbert Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
2. V.V. McLaughlin, S.L. Archer, and D.B. Badesch ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association J Am Coll Cardiol 53 2009 1573 1619
3. G. Kovacs, A. Berghold, and S. Scheidl Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review Eur Respir J 34 2009 888 894
4. M.M. Hoeper, H.J. Bogaard, and R. Condliffe Definitions and diagnosis of pulmonary hypertension J Am Coll Cardiol 62 2013 D42 D50
5. G. Simonneau, M.A. Gatzoulis, and I. Adatia Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 62 2013 D34 D41
6. J.D. Cogan, M.W. Pauciulo, and A.P. Batchman High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension Am J Respir Crit Care Med 174 2006 590 598
7. J.R. Thomson, R.D. Machado, and M.W. Pauciulo Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family J Med Genet 37 2000 741 745
8. R.E. Harrison, J.A. Flanagan, and M. Sankelo Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia J Med Genet 40 2003 865 871
9. E.D. Austin, L. Ma, and C. LeDuc Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension Circ Cardiovasc Genet 5 2012 336 343
10. L. Ma, D. Roman-Campos, and E.D. Austin A novel channelopathy in pulmonary arterial hypertension N Engl J Med 369 2013 351 361
11. H.P. Gurtner Aminorex and pulmonary hypertension. A review Cor Vasa 27 1985 160 171
12. R. Souza, M. Humbert, and B. Sztrymf Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Eur Respir J 31 2008 343 348
13. L. Savale, M.C. Chaumais, and V. Cottin Pulmonary hypertension associated with benfluorex exposure Eur Respir J 40 2012 1164 1172
14. D. Montani, E. Bergot, and S. Gunther Pulmonary arterial hypertension in patients treated by dasatinib Circulation 125 2012 2128 2137
15. L. Savale, C. Sattler, and S. Gunther Pulmonary arterial hypertension in patients treated with interferon Eur Respir J 44 2014 1627 1634
16. M. Humbert, O. Sitbon, and A. Chaouat Pulmonary arterial hypertension in France: results from a national registry Am J Respir Crit Care Med 173 2006 1023 1030
17. D.B. Badesch, G.E. Raskob, and C.G. Elliott Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry Chest 137 2010 376 387
18. M. Humbert, A. Yaici, and P. de Groote Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival Arthritis Rheum 63 2011 3522 3530
19. J.G. Coghlan, C.P. Denton, E. Grunig for the DETECT Study Group Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study Ann Rheum Dis 73 2014 1340 1349
20. B. Degano, O. Sitbon, and G. Simonneau Pulmonary arterial hypertension and HIV infection Semin Respir Crit Care Med 30 2009 440 447
21. O. Sitbon, C. Lascoux-Combe, and J.F. Delfraissy Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era Am J Respir Crit Care Med 177 2008 108 113
22. R.L. Benza, D.P. Miller, and R.J. Barst An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry Chest 142 2012 448 456
23. M.J. Krowka, D.P. Miller, and R.J. Barst Portopulmonary hypertension: a report from the US-based REVEAL Registry Chest 141 2012 906 915
24. P.M. Engelfriet, M.G. Duffels, and T. Moller Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease Heart 93 2007 682 687
25. M. Lapa, B. Dias, and C. Jardim Cardiopulmonary manifestations of hepatosplenic schistosomiasis Circulation 119 2009 1518 1523
26. C.J. dos Santos Fernandes, C.V. Jardim, and A. Hovnanian Survival in schistosomiasis-associated pulmonary arterial hypertension J Am Coll Cardiol 56 2010 715 720
27. C.J. Fernandes, B.A. Dias, and C.V. Jardim The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension Chest 141 2012 923 928
28. D. Montani, L.C. Price, and P. Dorfmuller Pulmonary veno-occlusive disease Eur Respir J 33 2009 189 200
29. M. Eyries, D. Montani, and B. Girerd EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension Nat Genet 46 2014 65 69
30. J.L. Vachiery, Y. Adir, and J.A. Barbera Pulmonary hypertension due to left heart diseases J Am Coll Cardiol 62 2013 D100 D108
31. G.G. Pietra, F. Capron, and S. Stewart Pathologic assessment of vasculopathies in pulmonary hypertension J Am Coll Cardiol 43 2004 25S 32S
32. M. Humbert, N.W. Morrell, and S.L. Archer Cellular and molecular pathobiology of pulmonary arterial hypertension J Am Coll Cardiol 43 12 Suppl S 2004 13S 24S
33. R.M. Tuder, S.L. Archer, and P. Dorfmuller Relevant issues in the pathology and pathobiology of pulmonary hypertension J Am Coll Cardiol 62 2013 D4 D12
34. M. Rabinovitch, C. Guignabert, and M. Humbert Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension Circ Res 115 2014 165 175
35. A. Huertas, F. Perros, and L. Tu Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay Circulation 129 2014 1332 1340
36. J.L. Cracowski, F. Chabot, and J. Labarere Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension Eur Respir J 43 2014 915 917
37. F. Soubrier, W.K. Chung, and R. Machado Genetics and genomics of pulmonary arterial hypertension J Am Coll Cardiol 62 2013 D13 D21
38. S. Rich, G.G. Pietra, and K. Kieras Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes Ann Intern Med 105 1986 499 502
39. M. Humbert, O. Sitbon, and A. Chaouat Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era Circulation 122 2010 156 163
40. O. Sitbon, R.L. Benza, and D.B. Badesch Validation of two predictive models for survival in pulmonary arterial hypertension Eur Respir J 2015 Apr 2 [E-pub ahead of print]
41. L.G. Rudski, W.W. Lai, and J. Afilalo Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography J Am Soc Echocardiogr 23 2010 685 713 quiz 786-8
42. M.M. Hoeper, S.H. Lee, and R. Voswinckel Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers J Am Coll Cardiol 48 2006 2546 2552
43. O. Sitbon, M. Humbert, and X. Jais Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation 111 2005 3105 3111
44. B.A. Borlaug, R.A. Nishimura, and P. Sorajja Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction Circ Heart Fail 3 2010 588 595
45. T. Thenappan, S.J. Shah, and M. Gomberg-Maitland Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction Circ Heart Fail 4 2011 257 265
46. H.J. Willens, J.A. Chirinos, and O. Gomez-Marin Noninvasive differentiation of pulmonary arterial and venous hypertension using conventional and Doppler tissue imaging echocardiography J Am Soc Echocardiogr 21 2008 715 719
47. S.F. Crawley, M.K. Johnson, and H.J. Dargie LA volume by CMR distinguishes idiopathic from pulmonary hypertension due to HFpEF J Am Coll Cardiol Img 6 2013 1120 1121
48. D. Mereles, N. Ehlken, and S. Kreuscher Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension Circulation 114 2006 1482 1489
49. S. Rich, E. Kaufmann, and P.S. Levy The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension N Engl J Med 327 1992 76 81
50. H. Frank, J. Mlczoch, and K. Huber The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension Chest 112 1997 714 721
51. V. Fuster, P.M. Steele, and W.D. Edwards Primary pulmonary hypertension: natural history and the importance of thrombosis Circulation 70 1984 580 587
52. K.M. Olsson, M. Delcroix, and H.A. Ghofrani Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) Circulation 129 2014 57 65
53. R.M. Tuder, C.D. Cool, and M.W. Geraci Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension Am J Respir Crit Care Med 159 1999 1925 1932
54. R.J. Barst, L.J. Rubin, W.A. Long Primary Pulmonary Hypertension Study Group A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 1996 296 301
55. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
56. O. Sitbon, M. Humbert, and H. Nunes Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788
57. D.B. Badesch, V.F. Tapson, and M.D. McGoon Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial Ann Intern Med 132 2000 425 434
58. G. Simonneau, R.J. Barst, and N. Galie Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800 804
59. V.V. McLaughlin, R.L. Benza, and L.J. Rubin Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial J Am Coll Cardiol 55 2010 1915 1922
60. Z.C. Jing, K. Parikh, and T. Pulido Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial Circulation 127 2013 624 633
61. V.F. Tapson, F. Torres, and F. Kermeen Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial Chest 142 2012 1383 1390
62. V.F. Tapson, Z.C. Jing, K.F. Xu for the FREEDOM-C2 Study Team Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial Chest 144 2013 952 958
63. H. Olschewski, G. Simonneau, N. Galie for the Aerosolized Iloprost Randomized Study Group Inhaled iloprost for severe pulmonary hypertension N Engl J Med 347 2002 322 329
64. D.J. Stewart, R.D. Levy, and P. Cernacek Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114 1991 464 469
65. A. Giaid, M. Yanagisawa, and D. Langleben Expression of endothelin-1 in the lungs of patients with pulmonary hypertension N Engl J Med 328 1993 1732 1739
66. D. Montani, R. Souza, and C. Binkert Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension Chest 131 2007 101 108
67. L.J. Rubin, D.B. Badesch, and R.J. Barst Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903
68. N. Galie, L. Rubin, and M. Hoeper Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial Lancet 371 2008 2093 2100
69. N. Galie, M. Beghetti, M.A. Gatzoulis Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study Circulation 114 2006 48 54
70. N. Galie, H. Olschewski, R.J. Oudiz Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation 117 2008 3010 3019
71. M. Clozel, A. Maresta, and M. Humbert Endothelin receptor antagonists Handb Exp Pharmacol 218 2013 199 227
72. T. Pulido, I. Adzerikho, R.N. Channick for the SERAPHIN Investigators Macitentan and morbidity and mortality in pulmonary arterial hypertension N Engl J Med 369 2013 809 818
73. A. Giaid, and D. Saleh Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension N Engl J Med 333 1995 214 221
74. N. Galie, H.A. Ghofrani, A. Torbicki for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2005 2148 2157
75. N. Galie, B.H. Brundage, H.A. Ghofrani for the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2009 2894 2903
76. F. Grimminger, G. Weimann, and R. Frey First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension Eur Respir J 33 2009 785 792
77. J.P. Stasch, P. Pacher, and O.V. Evgenov Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease Circulation 123 2011 2263 2273
78. H.A. Ghofrani, A.M. D'Armini, F. Grimminger for the CHEST-1 Study Group Riociguat for the treatment of chronic thromboembolic pulmonary hypertension N Engl J Med 369 2013 319 329
79. H.A. Ghofrani, N. Galie, F. Grimminger for the PATENT-1 Study Group Riociguat for the treatment of pulmonary arterial hypertension N Engl J Med 369 2013 330 340
80. M.M. Hoeper, and J. Granton Intensive care unit management of patients with severe pulmonary hypertension and right heart failure Am J Respir Crit Care Med 184 2011 1114 1124
81. E. Fadel, O. Mercier, and S. Mussot Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients Eur J Cardiothorac Surg 38 2010 277 284
82. J. Granton, O. Mercier, and M. De Perrot Management of severe pulmonary arterial hypertension Semin Respir Crit Care Med 34 2013 700 713
83. M. Humbert, E.M. Lau, and D. Montani Advances in therapeutic interventions for patients with pulmonary arterial hypertension Circulation 130 2014 2189 2208
84. J. Sandoval, J. Gaspar, and H. Pena Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension Eur Respir J 38 2011 1343 1348
85. O. Sitbon, X. Jais, and L. Savale Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study Eur Respir J 43 2014 1691 1697
86. V.V. McLaughlin, S.P. Gaine, and L.S. Howard Treatment goals of pulmonary hypertension J Am Coll Cardiol 62 2013 D73 D81
87. D.B. Taichman, J. Ornelas, and L. Chung Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report Chest 146 2014 449 475
88. N. Galie, and G. Simonneau The Fifth World Symposium on Pulmonary Hypertension J Am Coll Cardiol 62 Suppl D 2013 D1 D3
89. G. Simonneau, A. Torbicki, and M.M. Hoeper Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension Eur Respir J 40 2012 874 880
90. McLaughlin VV. Effect of selexipag on morbidity/mortality in pulmonary arterial hyertension: results of the GRIPHON study. Paper presented at: ACC.15; March 15, 2015; San Diego, CA.
91. M.M. Hoeper, R.J. Barst, and R.C. Bourge Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study Circulation 127 2013 1128 1138
92. S. Eddahibi, C. Guignabert, and A.M. Barlier-Mur Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia Circulation 113 2006 1857 1864
93. Y. Fukumoto, N. Yamada, and H. Matsubara Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension Circ J 77 2013 2619 2625
94. X. Jais, D. Launay, and A. Yaici Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases Arthritis Rheum 58 2008 521 531
95. ClinicalTrials.gov. Rituximab for treatment of systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01086540. Accessed March 15, 2015.
96. E.D. Michelakis, M.S. McMurtry, and X.C. Wu Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels Circulation 105 2002 244 250
97. ClinicalTrials.gov. Dichloroacetate (DCA) for the treatment of pulmonary arterial hypertension. 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01083524. Accessed March 15, 2015.
98. E. Spiekerkoetter, X. Tian, and J. Cai FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension J Clin Invest 123 2013 3600 3613
99. X.X. Wang, F.R. Zhang, and Y.P. Shang Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial J Am Coll Cardiol 49 2007 1566 1571
100. F.S. de Man, L. Tu, and M.L. Handoko Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension Am J Respir Crit Care Med 186 2012 780 789
101. H.J. Bogaard, R. Natarajan, and S. Mizuno Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats Am J Respir Crit Care Med 182 2010 652 660
102. S.L. Chen, F.F. Zhang, and J. Xu Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension) J Am Coll Cardiol 62 2013 1092 1100
103. A.E. Baruteau, E. Belli, and Y. Boudjemline Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients Eur J Cardiothorac Surg 47 2015 e105 e110
104. J.J. Esch, P.B. Shah, and B.A. Cockrill Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience J Heart Lung Transplant 32 2013 381 387
105. S. Meyer, V.V. McLaughlin, and H.J. Seyfarth Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey Eur Respir J 41 2013 1302 1307
106. A.M. Bassily-Marcus, C. Yuan, and J. Oropello Pulmonary hypertension in pregnancy: critical care management Pulmonary Med 2012 2012 709407
107. M. Bonnin, F.J. Mercier, and O. Sitbon Severe pulmonary hypertension during pregnancy Anesthesiology 102 2005 1133 1137
108. X. Jais, K.M. Olsson, and J.A. Barbera Pregnancy outcomes in pulmonary arterial hypertension in the modern management era Eur Respir J 40 2012 881 885
109. S. Rajdev, R. Benza, and V. Misra Use of Tandem Heart as a temporary hemodynamic support option for severe pulmonary artery hypertension complicated by cardiogenic shock J Invasive Cardiol 19 2007 E226 E229
110. M.B. Anderson, and M. O'Brien Use of the Impella 2.5 Microaxial pump for right ventricular support after insertion of Heartmate II left ventricular assist device Ann Thorac Surg 95 2013 e109 e110
111. R.C. Deano, C. Glassner-Kolmin, and M. Rubenfire Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study JAMA Int Med 173 2013 887 893